Related Experiment Video
Updated: Sep 17, 2025

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
Fibrillary glomerulonephritis: an observational study of clinical-pathological features and outcomes in patients from
Jean Patrick1, Madeline Charles-Rudwick1, Charlotte Quinn2
1Department of Renal Medicine, James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, UK.
Background:
Fibrillary glomerulonephritis (FGN) is a rare glomerulopathy characterized by randomly arranged fibrils within the mesangium and glomerular basement membrane. It has poor renal outcomes and no specific treatment. This retrospective study aimed to identify clinical-pathological predictors of outcomes in a multi-institutional cohort with histopathology performed at a single centre in the UK.
Methods:
Patients with biopsy proven FGN between 2015 and 2024 were identified using the Cambridge University Hospitals (CUH) histopathology database. Clinical data, including demographics, comorbidities, laboratory parameters, treatments and outcomes, were compared with findings from four other studies. Histological characteristics and DNAJB9 staining, where available, were analysed.
Results:
Thirty-five patients with FGN (2.8:1 female-to-male ratio) with a mean age of 62.8 years were identified. Autoimmune diseases, diabetes mellitus (DM) and malignancy (solid organ and haematological) were present in 28.5%, 34.2% and 20%, respectively. Nephrotic-range proteinuria was present in 58.8% and renal dysfunction in 91.4% at presentation. The most common histological pattern was mesangial proliferative/sclerosing followed by diffuse proliferative (DPGN). DNAJB9 staining was positive in all 13 tested patients. At a median 39 months follow-up, 51% progressed to end-stage renal disease (ESRD). Female sex, proteinuria and DPGN were significant predictors of ESRD on multivariate analysis. Although rituximab was associated with non-progression of disease, immunosuppression showed no statistically significant impact on outcomes.
Conclusion:
FGN is strongly associated with malignancy, autoimmune disease and DM. Prognosis remains poor, with progression to ESRD significantly influenced by proteinuria, DPGN and female sex.
Insights
Fibrillary glomerulonephritis (FGN) has poor renal outcomes. Female sex, proteinuria, and diffuse proliferative glomerulonephritis (DPGN) predict end-stage renal disease (ESRD) progression in FGN patients.
Area of Science:
- Nephrology
- Pathology
Background:
- Fibrillary glomerulonephritis (FGN) is a rare kidney disease characterized by abnormal fibril deposition.
- It is associated with poor renal outcomes and lacks specific treatments.
- Identifying predictors of FGN progression is crucial for patient management.
Purpose of the Study:
- To identify clinical and pathological predictors of outcomes in patients with FGN.
- To analyze a multi-institutional cohort with centralized histopathology review.
Main Methods:
- Retrospective analysis of 35 patients with biopsy-proven FGN (2015-2024).
- Clinical data, comorbidities, laboratory parameters, and outcomes were collected.
- Histological characteristics and DNAJB9 staining were analyzed.
Main Results:
- The cohort had a mean age of 62.8 years, with a 2.8:1 female-to-male ratio.
- Common comorbidities included diabetes mellitus (34.2%) and malignancy (20%).
- 51% progressed to end-stage renal disease (ESRD) within a median of 39 months. Female sex, proteinuria, and diffuse proliferative glomerulonephritis (DPGN) were significant predictors of ESRD.
Conclusions:
- FGN is linked to malignancy, autoimmune disease, and diabetes mellitus.
- Prognosis for FGN remains poor.
- Proteinuria, DPGN, and female sex significantly influence progression to ESRD.
More Related Videos
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Chronic Kidney Disease II: Clinical Manifestations

